Form D · Pharmaceuticals
Evolus, Inc.
Newport Beach, CA · CIK 0001570562
Offering snapshot reported Jul 17, 2020 · SEC filing
- Reported sold
- $40M Offering amount: $40M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 6, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 17, 2020 | Initial | $40,000,000 | No comparison | 1 | SEC filing |
| Feb 27, 2013 | Initial | $500,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-371264
Convertible Promissory Note
Source: Form D, filed Jul 17, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Rui Avelar | Executive |
| Simone Blank | Director |
| Scott Cannizzaro | Director |
| Peter Farrell | Director |
| David Gill | Director |
| John Gross | Director |
| Robert Hayman | Director |
| Michael Jafar | Executive |
| Vikram Malik | Director |
| J. Christopher Marmo | Director, Executive |
| David Moatazedi | Director, Executive |
| Karah Parschauer | Director |
| Lauren Silvernail | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
520 Newport Center Drive Suite 1200
Newport Beach, CA, 92660
Newport Beach, CA, 92660